Ms. Emily Jane Marlin, SOCIAL WORK Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1224 Smith Hill Road, East Meredith, NY 13757 Phone: 607-746-7288 |
News Archive
Oncolytics Biotech Inc. today announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018).
New research from Johns Hopkins School of Medicine reveals a high value of scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer. The study, featured in the February 2015 issue of the Journal of Nuclear Medicine, establishes the value of fourth and subsequent follow-up PET/CT scans in clinical assessment and management change in patients with the disease.
In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine.
Opioid prescriptions have been a known driver of the opioid epidemic, and it's now known that opioid prescriptions that last longer than five days are a risk factor for longer-term opioid use.
› Verified 4 days ago